Category: ACNR News

ACNR Podcast – celebrating 20 years of ACNR

It is a great pleasure to mark ACNR’s 20th anniversary with a new departure for the reviews section. This is our first podcast review. And what better inaugural podcast to review than the ACNR’s very own, in the form of an interview by Sri Kodali. Sri questions no less a pair than Rachael Hansford, ACNR…

Positive phase III data for Neurocrine’s Ingrezza in Huntington’s disease

Neurocrine Biosciences has recently announced that its pipeline asset, Ingrezza (valbenazine), achieved the primary endpoint of reducing the symptoms of chorea (involuntary muscle movements) associated with Huntington’s disease (HD) in the Phase III clinical trial, KINECT-HD (NCT04102579). This will propel Ingrezza into a dominant position in the HD market, due to its convenient once-daily dosing…

ACNR indexed in DOAJ (Directory of Open Access Journals)

DOAJ indexes and promotes quality, peer-reviewed open access journals from around the world. It is the most important community-driven, open access service in the world and has a reputation for advocating best practices and standards in open access. DOAJ’s basic criteria for inclusion have become the accepted way of measuring an open access journal’s adherence to standards…

Find ACNR articles in EuropePMC/PubMed

We have recently added the article Hallucinations in Parkinson’s disease to EuropePMC on behalf of authors Rimona Weil and Suzanne Reeves.  Is your work supported by funders on this list?  If you write about your work for ACNR, we can add your article to EuropePMC with no charges for you or your institution. Contact the…

ACNR joins Crossref

We’re delighted to announce that ACNR has joined Crossref, and will be allocating DOI’s to new articles. We have also started adding DOI’s to existing articles, but as we have been publishing for almost 20 years we have quite a lot of content to work through! If you have published an article with us in…